SCHEMBL5367092

SCHEMBL5367092

Cc1cc(Cc2ccc(=O)[nH]n2)cc(Oc2cccc(Cl)c2)c1C

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.66
SLC6A4 P31645 3/20 0.38
HTR2A P28223 1/20 0.38
KCNH2 Q12809 1/20 0.38
RHEB Q15382 2/20 0.36
PTGS1 P23219 1/20 0.36
PTGS2 P35354 1/20 0.36
SLC6A2 P23975 2/20 0.36
SLC6A3 Q01959 2/20 0.36
AKR1B1 P15121 1/20 0.36
AHR P35869 1/20 0.34
EGFR P00533 1/20 0.34
PRMT5 O14744 1/20 0.34
WDR77 Q9BQA1 1/20 0.34
HTR1A P08908 1/20 0.34
PPARG P37231 1/20 0.34
PPARD Q03181 1/20 0.34
MAPK8 P45983 1/20 0.34
PDE5A O76074 1/20 0.34
PDE9A O76083 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5368939 0.88 CYP3A4 (0.64) CYP3A4SLC6A4HTR2AKCNH2RHEB
SCHEMBL14570707 0.86 CYP3A4 (0.50) CYP3A4
SCHEMBL5365181 0.84 CYP3A4 (0.67) CYP3A4SLC6A4HTR2AKCNH2RHEB
SCHEMBL5370245 0.83 CYP3A4 (0.63) CYP3A4SLC6A4HTR2AKCNH2RHEB
SCHEMBL5377723 0.83 CYP3A4 (0.66) CYP3A4SLC6A4HTR2AKCNH2RHEB
SCHEMBL5372571 0.83 CYP3A4 (0.60) CYP3A4SLC6A4HTR2AKCNH2PTGS1
SCHEMBL5372601 0.82 CYP3A4 (0.62) CYP3A4SLC6A4HTR2AKCNH2RHEB
SCHEMBL5374289 0.82 CYP3A4 (0.64) CYP3A4AKR1B1AHRPRMT5WDR77
SCHEMBL5377627 0.82 CYP3A4 (0.64) CYP3A4SLC6A4HTR2AKCNH2RHEB
SCHEMBL5375418 0.81 CYP3A4 (0.60) CYP3A4SLC6A4HTR2AKCNH2AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7189718-B2 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2007-03-13 US disclosed
US-7189718-B2 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2007-03-13 US disclosed
EP-1608629-A1 BENZYL-PYRIDAZINONS AS REVERSE TRANSCRIPTASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-12-28 EP disclosed
US-20040198736-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2004-10-07 US disclosed
WO-2004085406-A1 BENZYL-PYRIDAZINONS AS REVERSE TRANSCRIPTASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2004-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198736-A1 Non-nucleoside reverse transcriptase inhibitors POLR1A, POLR2A, POLR2E CYP3A4 264/4885SLC6A4 2509/4885HTR2A 3525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.